Unit:
Τομέας ΚλινικοεργαστηριακόςLibrary of the School of Health Sciences
Author:
Sotiropoulos Georgios
Dissertation committee:
Μαρία Νταλαμάγκα, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπουσα
Αθανάσιος Παπαβασιλείου, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ευανθία Κασσή, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Σταυρούλα Κουλοχέρη, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Αγγελική Παπαπαναγιώτου, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Στυλιανή Κοκκόρη, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Πέτρος Μπακάκος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Ορμόνες του λιπώδους ιστού, φλεγμονώδεις παράγοντες, διαταραχές αιμόστασης και Μη Μικροκυτταρικός Καρκίνος του Πνεύμονα
Translated title:
Adipose tissue hormones, inflammatory and hemostatic factors, and Non Small Cell Lung Cancer
Summary:
Objectives: Chemerin and PAI-1 are emerging biomarkers at the intersection of inflammation, chemotaxis, thrombosis, fibrinolysis and metabolism. The aims of the present thesis were: 1) to explore the association between circulating chemerin and PAI-1 activity in resectable non-small cell lung cancer (NSCLC); 2) to study their diagnostic potential; and 3) to assess their associations with clinicopathological features of NSCLC.
Methods: In an adequately powered case-control study, plasma PAI-1 activity, chemerin, metabolic parameters, classic adipokines, hemostatic, inflammatory and tumor biomarkers were measured in 110 consecutive patients with resectable NSCLC and 110 healthy subjects matched on age, sex and date of blood draw.
Results: NSCLC patients exhibited significantly higher PAI-1 activity and serum chemerin levels compared to controls (p<0.001). In NSCLC cases, PAI-1 activity correlated with somatometric variables, insulin, WBC, antithrombin III, protein C, plasminogen, IL-6 and tumor size, whereas chemerin with Homeostasis model assessment score of insulin resistance (HOMA-IR), fibrinogen, plasminogen activity, tumor and inflammatory biomarkers, adiponectin, number of infiltrated lymph nodes and NSCLC stage. (p<0.05). Plasma PAI-1 activity and serum chemerin were independently associated with NSCLC beyond and above established risk factors for NSCLC (p<0.001). Plasminogen activity and body mass index emerged as independent predictors of PAI-1 activity in cases, whereas hemostatic parameters (platelet count and plasminogen activity), HOMA-IR, CYFRA 21-1, creatinine and plant food consumption emerged as independent predictors of circulating chemerin (p<0.05). Due to their high specificity, PAI-1 activity and serum chemerin could represent potentially useful parameters in ruling out NSCLC, alone or in combination with serum tumor markers associated with NSCLC.
Conclusions: PAI-1 activity and serum chemerin may represent potentially useful biomarkers in NSCLC associated with thrombotic, tumor-promoting and metabolic networks. More clinical studies are needed to explore whether PAI-1 activity and chemerin may be practical biomarkers in the risk assessment of NSCLC at the crossroads of hemostasis, inflammation and metabolism.
Main subject category:
Health Sciences
Keywords:
Chemerin, PAI-1 activity, NSCLC
Number of references:
237
